Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 2/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338132 | 0.90 | SIGMAR1 (0.35) | SIGMAR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1336152 | 0.88 | OPRK1 (0.36) | P2RX7PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1337786 | 0.88 | MAOB (0.36) | P2RX7 | |
| SCHEMBL1337037 | 0.84 | TACR1 (0.35) | PDE4APDE4BPDE4CPDE4DHTR2A | |
| SCHEMBL2028051 | 0.83 | WDR5 (0.35) | P2RX7HTR2AGRM2DRD4 | |
| SCHEMBL1335863 | 0.82 | MAOB (0.36) | P2RX7PREP | |
| SCHEMBL14007686 | 0.82 | HTR2A (0.32) | P2RX7HTR2AGRM2DRD4 | |
| SCHEMBL14007690 | 0.81 | P2RX3 (0.32) | P2RX7HTR2AGRM2DRD4 | |
| SCHEMBL3615763 | 0.81 | P2RX3 (0.32) | P2RX7HTR2AGRM2DRD4 | |
| SCHEMBL1337557 | 0.80 | P2RX7 (0.34) | P2RX7TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130178468-A1 | HIV INTEGRASE INHIBITORS | VACCA JOSEPH P (US) | 2013-07-11 | — | — | US | disclosed |
| US-8293731-B2 | HIV integrase inhibitors | Merck Sharp + Dohme Corp. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110275621-A1 | HIV INTEGRASE INHIBITORS | SCHERING CORPORATION | 2011-11-10 | — | — | US | disclosed |
| US-7968564-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100204201-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-7741315-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090054399-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054399-A1 | HIV INTEGRASE INHIBITORS | REV1, POLR1A, POLR2H | SIGMAR1 2935/4885P2RX7 3897/4885PDE4A 1768/4885 |
| US-20100204201-A1 | HIV INTEGRASE INHIBITORS | REV1, CDKN1A, CCNI | SIGMAR1 3235/4885P2RX7 4051/4885PDE4A 1944/4885 |
| US-20130178468-A1 | HIV INTEGRASE INHIBITORS | REV1, CDKN1A, CCNI | SIGMAR1 3235/4885P2RX7 4051/4885PDE4A 1944/4885 |
| US-20110275621-A1 | HIV INTEGRASE INHIBITORS | REV1, CDKN1A, CCNI | SIGMAR1 3235/4885P2RX7 4051/4885PDE4A 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.